Blagden SP, Billingham L, Brown LC, Buckland SW, Cooper AM, Ellis S, et al. Experimental Cancer Medicine Centres (ECMC) CID trials working group. Effective delivery of Complex Innovative Design (CID) cancer trials-a consensus statement. Br J Cancer. 2020;122:473–82.

Article  PubMed  PubMed Central  Google Scholar 

European Medicines Agency. A call to pool EU research resources into large-scale, multi-centre, multi-arm clinical trials against COVID-19. 2020. https://www.ema.europa.eu/en/documents/other/call-pool-eu-research-resources-large-scale-multi-centre-multi-arm-clinical-trials-against-covid-19_en.pdf

Peto L, Horby P, Landray M. Establishing COVID-19 trials at scale and pace: experience from the RECOVERY trial. Adv Biol Regul. 2022:100901.

Hayward G, Butler CC, Yu LM, Saville BR, Berry N, Dorward J, et al. Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk. BMJ Open. 2021;11:e046799.

Article  PubMed  Google Scholar 

Fisher BA, Veenith T, Slade D, Gaskell C, Rowland M, Whitehouse T, et al. CATALYST investigators. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet Respir Med. 2022;10:255–66.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. Guideline for good clinical practice E6(R2). 2016. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf

RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383:2030–40.

RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704.

Adshead F, Al-Shahi Salman R, Aumonier S, Collins M, Hood K, McNamara C, et al. A strategy to reduce the carbon footprint of clinical trials. Lancet. 2021;398:281–2.

Article  CAS  PubMed  Google Scholar 

Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O’Connor DJ, Shaaban AM, et al. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22:e435–45.

Article  CAS  PubMed  Google Scholar 

Patel MG, Dorward J, Yu LM, Hobbs FR, Butler CC. Inclusion and diversity in the PRINCIPLE trial. Lancet. 2021;397:2251–2.

Article  CAS  PubMed  Google Scholar 

Newman LA, Winn RA, Carethers JM. Similarities in risk for COVID-19 and cancer disparities. Clin Cancer Res. 2021;27:24–7.

Article  CAS  PubMed  Google Scholar 

PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;397:1063–74.

Article  Google Scholar